[1] Nusrat S, Khan MS, Fazili J, et al. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol, 2014, 20: 5442-5460.
[2] 周荣斌,林霖. 《急性上消化道出血急诊诊治流程专家共识(修订稿)》的阐释. 中国全科医学,2015,18:4021-4024.
[3] Moller S, Bendtsen F. Cirrhotic Multiorgan Syndrome. Dig Dis Sci, 2015, 60: 3209-3225.
[4] Sarin SK, Sharma P. Terlipressin: an asset for hepatologists. Hepatology, 2011, 54: 724-728.
[5] Sharma P, Sarin SK. Improved survival with the patients with variceal bleed. Int J Hepatol, 2011, 2011: 356919.
[6] Asfar P, Radermacher P, Cales P, et al. The effects of vasopressin and its analogues on the liver and its disorders in the critically ill. Curr Opin Crit Care, 2010, 16: 148-152.
[7] Seo YS, Park SY, Kim MY, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology, 2014, 60: 954-963.
[8] Magan AA, Khalil AA, Ahmed MH. Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. World J Gastroenterol, 2010, 16: 5139-5147.
[9] Salerno F, Guevara M, Bernardi M, et al. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int, 2010, 30: 937-947.
[10] Huang YY, Sun JY, Wang JY, et al. Terlipressin resolves ascites of cirrhotic rats through downregulation of aquaporin 2. J Int Med Res, 2012, 40: 1735-1744. |
